chartexchange

IceCure: 3 Key Takeaways for Long-Term Investors

The Motley Fool | Nov 18, 2026 3:13 PM EST

On its third-quarter and nine-month 2026 earnings call, held on Nov. 18, 2026, IceCure (NASDAQ:ICCM) announced that total revenue rose 26% to $2.6 million, driven by demand for ProSense, its system that freezes and destroys tumors. Long-term investors must weigh accelerating domestic sales momentum against an operating loss of $12.9 million and extended clinical study timelines. Three things management said stand out. Domestic adoption of ProSense is gaining speed as regional sales infrastructure takes hold. U.S. revenue surged 83% year over year in the first nine months of 2026, leading sales leadership to project sequential quarterly gains. Deploying dedicated sales and clinical support professionals in key regions like California and Florida allows the business to reach more medical institutions. This expanded commercial network provides the infrastructure required to train physicians and drive utilization. Continue reading

Read original article